In this study, we investigated the potential molecular and immunological differences resulting from production of the recombinant fusion proteins (Hybrid-1, comprising of the immunodominant antigens Ag85B and ESAT-6 from Mycobacterium tuberculosis) in two different expression systems, namely M. smegmatis and Escherichia coli. The fusion protein was successfully expressed and purified from both bacterial hosts and analyzed for any host-dependent post-translational modifications that might affect the immunogenicity of the antigen. We investigated the immunogenicity from both from E. coli-derived Hybrid-1 fusion and M.
Introduction
Tuberculosis (TB) is still a major cause of morbidity and mortality in the world today.
Currently, it is estimated that 2-3 million deaths occur worldwide from active TB and there are 8-10 million new cases per year, whilst a third of the world population are latently infected with the causative agent, Mycobacterium tuberculosis (Dye, 2006; Maher et al., 2007) . During latency, M. tuberculosis is able to survive and persist as an intracellular pathogen for years, by being able to modulate phagosomal maturation, preventing phagosomal-lysosome fusion and reducing acidity within the phagosome (Gupta et al., 2012; Russell, 2001) . M. tuberculosis also has significant interaction with components of the innate immune system e.g. toll-like receptors (TLRs), complement and lung surfactant proteins SP-A and SP-D, which play important roles in shaping adaptive immunity to TB infection in the host (Tsolaki, 2009 ). The only licensed vaccine being used currently against M. tuberculosis is M. bovis Bacillus Calmette-Guerin (BCG), which has been used worldwide since the early 1900s.
Whilst BCG has been shown to be protective against childhood forms of TB, its efficacy against adult active TB varies greatly, ranging from 0 to 85% Fine, 1995) . Improved vaccines are urgently needed, particularly to target the global epidemic of adult active TB, which is the most infectious form of the disease (Hanekom et al., 2008) . During the last few years, a number of new candidate vaccines against TB have now been trailed, with several vaccines showing improved efficacy (Andersen, 2007) . Among these candidates is the fusion protein Hybrid-1 or H1, which is based on the immunodominant antigens Antigen 85B (Ag85B) and the Early Secretory Antigenic Target (ESAT-6) from M. tuberculosis. The Hybrid-1 fusion protein is at the forefront of candidate vaccines against TB and has been extensively tested in a number of studies (Agger et al., 2008; Dietrich et al., 2007; Langermans et al., 2005; Olsen et al., 2004; van Dissel et al., 2010; van Dissel et al., 2011; Weinrich Olsen et al., 2001) . A recent variant has also been fused to the latency associated protein Rv2660c (H56) that promises efficacy against pre-and post exposure (latent) TB (Aagaard et al., 2011 ). The majority of tested vaccine candidate antigens are heterologously expressed in various strains of the common laboratory organism Escherichia coli (E. coli), in spite of the fact that the protein folding and post-translational modification mechanism in the pathogen might be very different, compared to the host mycobacterium. Protein lacking the native mycobacterial milieu and modifications may be less immunologically active . Posttranslational modifications such as methylation have been shown to alter the immunogenicity of recombinant proteins when comparisons were made between native mycobacterial protein versus the recombinant protein expressed from E. coli (Menozzi et al., 1998; Pethe et al., 2002; Temmerman et al., 2004) . The purification of native proteins from M. tuberculosis or M. bovis BCG for biochemical and immunological analysis is a complex and laborious process, often resulting in poor yields of protein (Delogu and Brennan, 1999; Menozzi et al., 1996) . Recombinant expressions systems have been developed recently that can be used in fast-growing non-pathogenic mycobacteria. These systems have made use of modified mycobacterial plasmids that have been engineered to over-express protein, via the hsp60 promoter (Curcic et al., 1994; Delogu et al., 2004; DeMaio et al., 1997; Dziadek et al., 2002; O'Donnell et al., 1994) . Inducible systems for mycobacteria expression have also been developed, using tetracycline induction, which provide controlled amounts of protein expression (Blokpoel et al., 2005; Carroll et al., 2005; Ehrt et al., 2005; Triccas et al., 1998) . Using such systems has potential in producing recombinant proteins with features that are native to those in M. tuberculosis, free from lipopolysaccharide (LPS) contamination, thus facilitating its use as an optimum vaccine candidate or new diagnostic marker (Masungi et al., 2002) .
The aim of the present study was to develop a system of expression in M. smegmatis that would allow the expression of antigens from M. tuberculosis and their efficient purification, with the resultant recombinant protein resembling the native antigen. We therefore describe the expression of the Hybrid-1 fusion protein in E. coli and M.
smegmatis, using mycobacterial-shuttle plasmid vectors (Blokpoel et al., 2005; Wiles et al., 2005) . The expresssion vector used here contains the tetRO region from the Corynebacterium glutamicum TetZ, making expression of genes cloned downstream of tetRO responsive to tetracycline We demonstrate the purification of the recombinant Hybrid-1 proteins from both bacterial hosts and analysis of their biochemical and immunological characteristics, in order to determine whether there are any differences in their immunogenicity. Tween-80 (Sigma). All Escherichia coli strains were grown on LB-agar plates or in LB broth. When needed, kanamycin was added at a final concentration of 50μg/ml for E. coli and hygromycin was added at a concentration of 50 μg/ml for M. smegmatis.
Materials and Methods

Bacterial strains and growth conditions
Cloning of Hybrid1fusion into mycobacteria shuttle vectors
The pMCT6 plasmid containing the gene fusion Ag85B and ESAT-6 (Hybrid-1) was constructed as previously described (Weinrich Olsen et al., 2001 ). The hybrid-1 fusion was amplified from pMCT6 using, Ag85B-HB-forward primer ( PCR products were purified (Qiagen, UK) and digested by BamHI and SpeI enzymes (New England Biolabs, UK) and positionally cloned into the tetracycline-inducible vector pMind, described previously (Blokpoel et al., 2005) and the pSHKLx1 shuttle vector, . Both plasmids pMind and pSHKLx1 are E.colimycobacteria shuttle plasmids containing kanamycin and hygromycin selection markers. The pSHKLx1 also contains the constitutively expressed promoter hsp60 from M. tuberculosis H37Rv . The luxAB reporter genes in pSHKLx1 were replaced with the Hybrid-1 fusion, via the BamHI and SpeI sites.
Both pMind (Hybrid-1) and pSHK (Hybrid-1) were transformed into E. coli strains DH5a and BL21 (Invitrogen, UK), using the CaCl 2 method (Sambrook, 2000) and pSHK (Hybrid-1) expressed in E. coli strain BL21 (Invitrogen, UK). Vectors pMind (Hybrid-1) and pSHK (Hybrid-1) were introduced into M. smegmatis by electroporation, using the protocol previously described (Parish and Stoker, 1998) .
Expression conditions
For M. smegmatis starter cultures were set up consisting of pMind ( Lysates from both M. smegmatis and E. coli were then size-fractionated using gelfilteration S-100 and S-10 spin columns (Amicon, Millipore) to exclude protein outside the range of 10-100kDa. This fractionated lysate was then passed over a 1 ml HisTrap HP Ni-affinity sepharose column (GE Healthcare) and eluted with 500mM
imidazole. Eluted fractions were analyzed on SDS-PAGE and Coomassie staining.
Positive fractions were then further purified by FPLC (AKTA, GE healthcare) by loading onto a 1 ml HisTrap HP column (GE Healthcare). For the purification a gradient of imidazole concentration was used, from 10 mM (wash buffer, 20 mM sodium phosphate, 0.5 M NaCl and 10 mM imidazole, pH 7.4) to 0.5 M (elution buffer, 20 mM sodium phosphate, 0.5 M NaCl and 0.5 M imidazole, pH 7.4). Eluted fractions were tested for the presence of the Hybrid-1 fusion protein, by immunoblotting. Protein concentration of the final pooled purified sample of hybrid 1 was determined using the BCA method (Piercenet). H1 (EC, SSI) was produced and purified as previously described (Weinrich Olsen et al., 2001 ).
SDS-PAGE and immunoblots
Cell fractions were analyzed with the PhastSystem (Amersham) using 12% SDS-PAGE gel and transfer to nitrocellulose membrane (Laemmli, 1970) . This was further interrogated using anti-His tag (Invitrogen), anti-Ag85-TD17 and anti-ESAT-6 -HYB76-8 antibodies (obtained from SSI).
Post-translational modification assays
Protein fractions on Immunoblots were analyzed for glycosylation using the GLYCO-PRO kit (Sigma-Aldrich) and for phosphorylation by the PhosDecor kit (SigmaAldrich).
Mass spectrometry
Purified proteins were excised from SDS-PAGE gels and subjected to MALDI-TOF mass spectrometry, using MASCOT to identify the peptides. This was performed at
Hammersmith Hospital, Imperial College, London.
Immunization study
Immunogenicity of the M. smegmatis derived (H1 (MS, IC)) and E. coli derived (H1 (EC, IC)) Hybrid1 proteins were tested, together with an E. coli Hybrid-1 preparation previously published (H1 (EC, SSI)) (Weinrich Olsen et al., 2001) . The experiments on all three antigens were done using the methods outlined recently (Agger et al., 2008) . Briefly, mice were immunized three times, intramuscularly, at 3-week intervals, using a volume of 200 μl. All mice received a dose of adjuvant (250μg Dimethyldioctadecylammonium (DDA)/50 μg a,a'-trehalose 6,6'-dibehenate (TDB)) with 2μg of Hybrid1 antigen preparation.
Splenocyte cultures
Mice were rested for 3 weeks following the third immunisation, after which they were culled and spleen harvested. Cultures of splenocytes were obtained by homogenizing the organ into complete RPMI (RPMI 1640 supplemented with 5 x 10 -5 M 2-mercapthoethanol, 1 mM glutamine, 1% penicillin-streptomycin, 1% HEPES and 10% fetal calf serum all from Gibco (Invitrogen, Carlsbad, CA). Subsequently, cells
were washed twice and adjusted to a final concentration of 2.6 x 10 5 cells/well in a total volume of 200 μl/well. Splenocytes were re-stimulated with purified antigen at 5µg/ml, whereas Concanavalin A (Con A) at a concentration of 5µg/ml was used as a positive control for cell viability and medium used as a negative control. Ag85B and ESAT-6 antigen peptides were tested (E6-P1 and 85B-P63), as well as recombinant Ag85B, the ESAT-6 dimer protein dESAT-6, and the three hybrid1 antigens (H1 (EC, IC), H1 (MS, IC) and H1 (EC, SSI). Culture supernatants were harvested from parallel cultures after 72 h of incubation for the investigation of IFN-γ by ELISA performed as previously described (Dietrich et al., 2007) . protein is shown in Figure 1 . In both E. coli and M. smegmatis hosts, the expected size of the 35 KDa Hybrid-1 fusion proteins was obtained. In E. coli, expression did not require induction, since the pSHK (Hybrid-1) was under the control of the constitutive promoter hsp60. After 1hr, expression was detected and this was increased after overnight incubation. In M. smegmatis, the expression of the Hybrid-1 fusion was also detected after just 1 hr of induction with 20ng/ml of tetracycline. There did not appear to be significant increase in the levels of expression after 4hrs. The 35KDa band obtained was confirmed to be the Hybrid-1 fusion protein by immunoblotting, using anti-His tag antibody (results not shown).
Purification of the histidine-tagged Hybrid-1 fusion protein in E. coli and M. smegmatis
We next determined whether our expression of the Hybrid-1 fusion protein in E. coli and M. smegmatis allowed for the efficient purification of the 35KDa protein using the histidine tag on its N-terminus. A similar approach has been used before to purify proteins from mycobacteria successfully, without the histidine tag compromising the function or immunogenicity of the protein (Crowe et al., 1994; Triccas et al., 1998) .
Lysates of the M. smegmatis were obtained using a French Press cell disrupter and then size fractionated. These fractions were then past over a HIS-Trap column with varying amounts of imidazole (10mM, 20mM and 50mM), before bound protein was washed off with 250mM of imidazole. The same process was also used for the E. coli
Hybrid-1 fusion protein purification, except that E. coli cells were disrupted using
Bugbuster lysis buffer. Purified fractions from the His-trap from E. coli and M.
smegmatis were run on a 12% SDS-PAGE gel, in order to examine the purity of the protein extracts. Although a distinct 35KDa band was observed (confirmed by immunoblot with anti-HIS tag antibody), there were also contaminating proteins still present (results not shown). Pooled fractions of HIS-trap purified protein were therefore subjected to further standard gel filtration fractionation, using an automated AKTA FPLC system, in order to remove contaminating host proteins (Figure 2 ). The presence of HIS-tagged fusion protein was confirmed using anti-HIS tag antibody.
The yield of protein obtained for the M. smegmatis-derived Hybrid-1 is 5mg/L of culture, whilst for E. coli-derived Hybrid-1 it was 0.5mg/L of culture.
Characterization of the Hybrid-1 fusion protein in E. coli and M. smegmatis
Anti-Ag85B or ESAT-6 specific monoclonal antibodies of well-defined specificity (obtained from the SSI, Figure 3 ), were used to identify recombinant proteins via
immunoblotting. This showed that the M. smegmatis-derived Hybrid-1 fusion protein was intact (Figure 4 ). However, using the same monoclonal antibodies, the E. coli Hybrid-1 protein was shown to have lost the ESAT-6 epitope recognised by the monoclonal antibody HYB76-8 ( Figure 4B ). Positive signals for monoclonal antibody TD17 indicated that a full length Ag85B was present. The epitope for HYB76-8 has been mapped to the start of the ESAT-6 molecule suggesting that the whole of the ESAT-6 portion has been deleted from the E. coli-derived Hybrid-1.
In order to further investigate this truncation of the E. coli-derived Hybrid-1, we carried out MALDI-TOF mass spectrometry, using MASCOT to identify the peptides obtained. Peptides were obtained that were identified as Ag85B (Figure 3 ), being as follows: MS-pep1 (VQFQSGGNNSPAVYLLDGLR) and MS-pep2 (AADMWGPSSDPAWERNDPTQQ). No ESAT-6 peptides were identified and this was consistent with the pattern of antibody staining obtained ( Figure 4B ).
Post-translational modifications were sought using commercially available gel staining kits, but there was no evidence of either glycosylation or phosphorylation in the hybrid-1 fusion from M. smegmatis (results not shown).
Immunogenicity of the Hybrid-1 fusion protein in E. coli and M. smegmatis in mice
In order to compare the immunogenicity of the M. smegmatis-and E. coli-derived
Hybrid-1 proteins, all three antigens were evaluated using 3 subcutaneous injections at 3 weeks intervals of 2µg of protein in DDA-TDB adjuvant CAF01. In addition, a reference Hybrid-1 fusion also expressed in E. coli and obtained from the SSI (H1, (EC, SSI)) was included for comparison. Animals were rested for 3 weeks after the third immunization, after which they were culled and the spleens were harvested.
Splenocytes were re-stimulated with antigen at 5µg/ml for 72 hours, and then IFN-γ levels in the culture supernatants were measured by ELISA in the culture supernatants. A range of Ag85B and ESAT-6 peptides were tested, as well as the whole antigens from the various sources, and the levels of IFN-γ obtained are shown for a selection ( Figure 5 ). There was little difference in the pattern of reactivity observed from all three proteins analyzed, with even the truncated protein (H1 (EC, IC)) showing very similar levels of reactivity to the two full length proteins H1 (MS, IC) and H1 (EC, SSI). Immunisation with all three H1 proteins led to recognition of the Ag85B recombinant protein and the previously identified CD4 epitope QDAYNAAGGHNAVFN, represented by the Ag85B-P63 peptide (Bennekov et al., 2006) . However, the Hybrid-1 protein from E. coli (H1 (EC, IC)), missing the ESAT-6 portion of the fusion, did not react in the stimulation assay to either the ESAT-6 dimer (dESAT-6), or to the peptide E6-P1, which maps to the deleted region. This further confirms the loss of this region in the fusion protein.
Discussion
Expression of recombinant proteins in fast-growing non-pathogenic mycobacteria has been used extensively, as a result of the recent developments in Mycobacterial shuttle vectors. In the present study, our goal was to express recombinant fusion protein coli BL21 has cleaved the expressed fusion in order to keep the protein soluble. It is interesting to note that truncated forms of ESAT-6 have been identified from M.
tuberculosis culture filtrate, showing loss of 11 residues at the C-terminal end of the antigen, but this did not affect its binding to the 10 KDa culture filtrate protein (CFP10) .
No evidence was found of either phosphorylation or glycosylation in the M. (Temmerman et al., 2004) . Moreover, acetylated and non-acetylated forms of ESAT-6, show differential binding to the antigen CFP10 .
smegmatis-derived
In M. bovis BCG as a host, expression of recombinant protein was found to be significantly lower with the inducible tetA (present in pMind), than the strong mycobacterial promoter hsp60 (Blokpoel et al., 2005) . However, the same study also found that the magnitude of induction of tetA was approximately 50 times higher in fast-growing mycobacteria (M. smegmatis), than slow growing mycobacteria (M.
tuberculosis, and M. bovis BCG) (Blokpoel et al., 2005) . The inducible pMind system described in the present study may not be suitable for over-expression of recombinant antigens for high yields, but is better suited when controlled expression is required in a situation where a gene product may be toxic to the mycobacterial host cell. A better regulated version of this system has recently been published (Williams et al., 2010) .
Similarly, the inducible pMind system provides a useful system to study mycobacterial pathogenesis, by regulating the expression of mycobacterial genes, using antisense mRNA to knockdown specific gene products (Blokpoel et al., 2005) .
It is also preferred to express recombinant mycobacterial proteins in mycobacterial hosts, since a number of proteins are post-translationally modified in mycobacteria and therefore cannot be expressed as a native protein in the E. coli host.
Previously, other expression systems have been used, that contain alternative promoters such as the M. smegmatis acetamidase promoter and the β-lactamase promoter of M. fortuitum (Triccas et al., 1998) .
There have been studies showing the advantage of recombinant proteins expressed and purified from mycobacterial hosts versus to E. coli (Garbe et al., 1993; Triccas et al., 1998; Triccas et al., 1996) , with one study showing that a recombinant M. leprae antigen expressed in M. smegmatis was only recognized by the antisera from leprosy patients .
The addition of the HIS-tag allows for a simple and effective purification of the fusion. The HIS-tag on the Hybrid-1 fusion of both the E. coli-derived protein and M.
smegmatis protein also does not appear to have affected the confirmation of the protein and there is little difference in the T-cell responses, when compare to the E coli derived Hybrid-1 protein from the SSI, which lacks the HIS-tag. A similar finding was also demonstrated in the analysis of another mycobacterial antigen .
In conclusion, we have provided proof of principle evidence that vaccine candidates from M. tuberculosis can be expressed in a surrogate mycobacterial host and sufficient protein obtained for immunological and biochemical analysis. The expression systems described in this study could be used to test other M. tuberculosis antigens in preparation for obtaining an optimal TB vaccine, facilitating the analysis or their structure, function and antigenicity. smegmatis Hybrid-1. The E. coli Hybrid-1 was also purified using this method (not shown). smegmatis Hybrid-1 probed with Anti-HIS antibody, respectively. were compared with an E. coli Hybrid-1 prepared at the SSI, Denmark. C57BL/6J
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